Ritter Pharmaceuticals Inc (RTTR) Stock Rating Reaffirmed by Maxim Group
Ritter Pharmaceuticals Inc (NASDAQ:RTTR)‘s stock had its “buy” rating reissued by stock analysts at Maxim Group in a research report issued to clients and investors on Monday.
Separately, Zacks Investment Research raised shares of Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 20th.
Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 2.30 on Monday. Ritter Pharmaceuticals has a 12-month low of $0.98 and a 12-month high of $2.63. The stock has a 50 day moving average price of $1.60 and a 200-day moving average price of $1.55. The stock’s market cap is $19.74 million.
Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.14. Equities analysts anticipate that Ritter Pharmaceuticals will post ($1.38) EPS for the current fiscal year.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.